NASDAQ:ONVO Organovo - ONVO Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Organovo Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.94 +0.20 (+11.49%) (As of 02/8/2023 12:00 AM ET) Add Compare Share Share Today's Range$1.74▼$1.9450-Day Range$1.41▼$1.9452-Week Range$1.37▼$4.67Volume222,935 shsAverage Volume41,541 shsMarket Capitalization$16.90 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media About Organovo (NASDAQ:ONVO) StockOrganovo Holdings, Inc. is engaged in the development of bioprinted human tissues that emulate human biology and disease. Its three-dimensional human tissue platform is enabled by its proprietary NovoGen Bioprinters and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company was founded on January 30, 2012 and is headquartered in San Diego, CA.Read More Receive ONVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Organovo and its competitors with MarketBeat's FREE daily newsletter. Email Address ONVO Stock News HeadlinesFebruary 2, 2023 | americanbankingnews.comOrganovo (NASDAQ:ONVO) Receives New Coverage from Analysts at StockNews.comOctober 25, 2022 | finance.yahoo.comOrganovo Holdings, Inc. (ONVO)February 9, 2023 | Vantage Point (Ad)Predict These Market Breakouts with A.I.We’re looking for breakouts using a simple A.I. tool that you've got to see in our Live Free A.I. Market Training. Breakouts can make or break your trading, so it's critical you know how to predict them 1 - 3 days ahead. They happen at any moment, and they're easier to find with A.I. on your side. October 17, 2022 | finance.yahoo.comTrends in 3D-Printing Materials Technology and the Global Market for the Most Promising New 3D-Printing Materials Applications - Yahoo FinanceOctober 12, 2022 | benzinga.comHuman Liver Models Market Size Share Trends Growth Demand and Competitive Analysis Insights 2022-2029 | D - BenzingaOctober 9, 2022 | globenewswire.com3D Bioprinting Market Size to Touch Valuation of $1.5 Billion by 2028 | Inkjet Technology Generates More than 38% Revenue of Bioprinting Market - GlobeNewswireOctober 3, 2022 | seekingalpha.comARKG: Too Hard To Pin Down, Too Volatile For Comfort (BATS:ARKG) - Seeking AlphaSeptember 30, 2022 | businesswire.comGlobal Human Liver Model Market Report 2022: Emerging 3D and 2D Trends in Modeling Human Liver Disease in Vitro Fuel Growth - ResearchAndMarkets.com - Business WireFebruary 9, 2023 | Vantage Point (Ad)Predict These Market Breakouts with A.I.We’re looking for breakouts using a simple A.I. tool that you've got to see in our Live Free A.I. Market Training. Breakouts can make or break your trading, so it's critical you know how to predict them 1 - 3 days ahead. They happen at any moment, and they're easier to find with A.I. on your side. September 29, 2022 | businesswire.com3D Bioprinting Global Market Report 2022: Long-term Forecasts to 2026 & 2031 Featuring Organovo Holdings, Allevi, Cellink, Aspect Biosystems, & 3D Systems - ResearchAndMarkets.com - Business WireSeptember 23, 2022 | benzinga.comWhy Spero Therapeutics Is Trading Higher By Over 105%; Here Are 21 Stocks Moving Premarket - American Vir - BenzingaSeptember 22, 2022 | uk.investing.comWhy Spero Therapeutics Is Trading Higher By Over 105%; Here Are 21 Stocks Moving Premarket By Benzinga - Investing.com UKSeptember 16, 2022 | nasdaq.comPre-market Movers: DWIN, SES, KSPN, NRBO, EPM… - NasdaqSeptember 16, 2022 | uk.investing.comWhy Applied Optoelectronics Is Trading Higher By Around 31%; Here Are 21 Stocks Moving Premarket By Benzinga - Investing.com UKSeptember 14, 2022 | rttnews.comPre-market Movers: DWIN, SES, KSPN, NRBO, EPM… - RTTNewsSeptember 6, 2022 | globenewswire.comOrganovo to Participate in the H.C. Wainwright 24th Annual - GlobeNewswireSeptember 6, 2022 | globenewswire.comOrganovo Announces Postponement of Annual Meeting of Stockholders - GlobeNewswireSeptember 6, 2022 | finance.yahoo.comOrganovo Announces Postponement of Annual Meeting of StockholdersSeptember 6, 2022 | finance.yahoo.comOrganovo to Participate in the H.C. Wainwright 24th Annual Global Investment ConferenceSeptember 6, 2022 | benzinga.com(AHI), (ALNA) – Why DWAC Is Trading Lower By Around 19%; Here Are 32 Stocks Moving Premarket - BenzingaSeptember 5, 2022 | finance.yahoo.comUSD 1.18 billion Growth in Human Organoids Market with 44% of the Contribution from North America - Technavio - Yahoo FinanceAugust 30, 2022 | globenewswire.comIndustrial 3D Printing Market Expected to Reach $107.7 Billion By 2031: Allied Market Research - GlobeNewswireAugust 12, 2022 | finance.yahoo.comGlobal 4D Printing Market is Predicted to Grow at a CAGR of ~40% during 2022-2031; Increasing Adoption of Novel 4D Printing in Biomedical Sciences such as Prostheses to Elevate Growth - Research Nester - Yahoo FinanceJuly 28, 2022 | globenewswire.comBy 2028, Demand for Global 3D Printing in Healthcare Market Size to Surpass US$ 3120.06 Million, at a 19.02% CAGR Growth: Comprehensive Research Report by Facts & Factors - GlobeNewswireJuly 20, 2022 | finance.yahoo.comThe Global Human Organoids Market is expected to grow by $ 1.18 bn during 2022-2026, accelerating at a CAGR of 16.9% during the forecast period - Yahoo FinanceJuly 20, 2022 | uk.finance.yahoo.comThe Global Human Organoids Market is expected to grow by $ 1.18 bn during 2022-2026, accelerating at a CAGR of 16.9% during the forecast period - Yahoo Finance UKJuly 19, 2022 | finance.yahoo.comOutlook on the 3D Printing Software and Services Global Market to 2031 - Cost-Effectiveness, Greater Design Flexibility, and Low Wastage are Driving Growth - Yahoo FinanceSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ONVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Organovo and its competitors with MarketBeat's FREE daily newsletter. Email Address ONVO Company Calendar Last Earnings11/10/2022Today2/08/2023Next Earnings (Estimated)2/13/2023Fiscal Year End3/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ONVO CUSIPN/A CIK1497253 Webwww.organovo.com Phone(858) 224-1000FaxN/AEmployees12Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,450,000.00 Net MarginsN/A Pretax Margin-757.32% Return on Equity-41.86% Return on Assets-37.67% Debt Debt-to-Equity RatioN/A Current Ratio17.54 Quick Ratio17.54 Sales & Book Value Annual Sales$1.50 million Price / Sales11.26 Cash FlowN/A Price / Cash FlowN/A Book Value$3.47 per share Price / Book0.56Miscellaneous Outstanding Shares8,710,000Free Float8,364,000Market Cap$16.90 million OptionableOptionable Beta1.05 Key ExecutivesKeith MurphyExecutive Chairman & Chief Executive OfficerThomas P. HessChief Financial & Accounting OfficerJeffrey N. MinerChief Scientific OfficerCurtis TyreeSenior VP-Strategy & Business DevelopmentSteve E. KunszaboVP-Investor Relations & Corporate CommunicationsKey CompetitorsTitan PharmaceuticalsNASDAQ:TTNPGenetic TechnologiesNASDAQ:GENEInhibikase TherapeuticsNYSE:IKTBrookline Capital AcquisitionNASDAQ:BCACIgnyte AcquisitionNASDAQ:IGNYView All CompetitorsInsiders & InstitutionsSumitomo Mitsui Trust Holdings Inc.Sold 6,624 shares on 1/30/2023Ownership: 5.221%ARK Investment Management LLCSold 60,565 shares on 1/24/2023Ownership: 2.460%Vanguard Group Inc.Bought 13,153 shares on 11/15/2022Ownership: 3.249%Renaissance Technologies LLCSold 38,200 shares on 11/14/2022Ownership: 1.376%View All Institutional Transactions ONVO Stock - Frequently Asked Questions How have ONVO shares performed in 2023? Organovo's stock was trading at $1.41 at the beginning of 2023. Since then, ONVO shares have increased by 37.6% and is now trading at $1.94. View the best growth stocks for 2023 here. When is Organovo's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, February 13th 2023. View our ONVO earnings forecast. How were Organovo's earnings last quarter? Organovo Holdings, Inc. (NASDAQ:ONVO) issued its quarterly earnings data on Thursday, November, 10th. The medical research company reported ($0.38) EPS for the quarter. The medical research company earned $0.08 million during the quarter. When did Organovo's stock split? Organovo shares reverse split on the morning of Wednesday, August 19th 2020. The 1-20 reverse split was announced on Monday, August 17th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, August 18th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What is Taylor Crouch's approval rating as Organovo's CEO? 3 employees have rated Organovo Chief Executive Officer Taylor Crouch on Glassdoor.com. Taylor Crouch has an approval rating of 38% among the company's employees. This puts Taylor Crouch in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Organovo own? Based on aggregate information from My MarketBeat watchlists, some companies that other Organovo investors own include Brainstorm Cell Therapeutics (BCLI), NVIDIA (NVDA), Aerojet Rocketdyne (AJRD), Blackstone (BX), LADENBURG THALM/SH SH (LTS), Advanced Micro Devices (AMD), Exelixis (EXEL), Micron Technology (MU), Novavax (NVAX) and OPKO Health (OPK). What is Organovo's stock symbol? Organovo trades on the NASDAQ under the ticker symbol "ONVO." Who are Organovo's major shareholders? Organovo's stock is owned by a number of retail and institutional investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (5.22%), ARK Investment Management LLC (2.46%) and Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends. How do I buy shares of Organovo? Shares of ONVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Organovo's stock price today? One share of ONVO stock can currently be purchased for approximately $1.94. How much money does Organovo make? Organovo (NASDAQ:ONVO) has a market capitalization of $16.90 million and generates $1.50 million in revenue each year. The medical research company earns $-11,450,000.00 in net income (profit) each year or ($1.37) on an earnings per share basis. How can I contact Organovo? Organovo's mailing address is 440 STEVENS AVENUE SUITE 200, SOLANA BEACH CA, 92075. The official website for the company is www.organovo.com. The medical research company can be reached via phone at (858) 224-1000 or via email at ir@organovo.com. This page (NASDAQ:ONVO) was last updated on 2/9/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.